Skip to main content

Table 3 Incidence of adverse events

From: Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study

Event AS group (n = 62) SOX group (n = 81) p-Value
Grade1/2 Grade3/4 Grade1/2 Grade3/4
Leukocytopenia 3 (4.84%) 3 (4.84%) 2 (2.47%) N/A 0.0800
Anemia 2 (3.23%) N/A 1 (1.23%) N/A 0.4207
Thrombocytopenia 1 (1.61%) 1 (1.61%) 5 (6.17%) N/A 0.4000
Vomiting 2 (3.23%) N/A 3 (3.70%) N/A 0.8816
Diarrhea 2 (3.23%) N/A 2 (2.47%) N/A 0.7915
Hepatic dysfunction 1 (1.61%) N/A 1 (1.23%) N/A 0.8507
Peripheral neurotoxicity 3 (4.84%) N/A 2 (2.47%) N/A 0.5611
Hand-foot syndrome 3 (4.84%) N/A 2 (2.47%) N/A 0.5611
Alopecia 3 (4.84%) N/A 2 (2.47%) N/A 0.5611